Jump to content

How do you solve device mismatch for your patients with COPD?

allnurses allnurses (Admin) Columnist Innovator Expert Nurse

Specializes in Largest Community Of Nurses, Students, & Educators.

Do you and your colleagues have the same treatment approach?

Device-specific considerations may play a large role in determining the proper treatment course for your patients with COPD. Device mismatch can have consequences such as poor inhaler technique and/or suboptimal symptom control over time.1 Take this survey to show your colleagues how you are mitigating device mismatch.

If you and your patients are experiencing the frustrations of device mismatch, consider LONHALA® MAGNAIR® (glycopyrrolate)

Being matched to the wrong device can interfere with your COPD patients’ treatment. To ensure the right fit, the Global Initiative for Chronic Obstructive Pulmonary Disease recommends continuous reassessment of treatment at every visit.1 For your patients who may need another option, there’s LONHALA MAGNAIR.

LONHALA MAGNAIR is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. LONHALA MAGNAIR is not a rescue medication.

*LONHALA MAGNAIR is not indicated to decrease the risk of exacerbation nor
improve cognitive/physical capacity.

GOLD does not endorse any specific treatments.

Reference:

  1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2020:1-125.

To see if LONHALA MAGNAIR could be right for your patients with COPD, visit www.sunovionprofile.com/lonhala-magnair.

This survey is sponsored by Sunovion Pharmaceuticals.

IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy.

LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%).

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Patient Information for LONHALA MAGNAIR at www.sunovionprofile.com/lonhala-magnair.

INDICATION

LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

LONHALA and symbol.png.ab37f53d768f4293e64727d2d9e4f914.png are registered trademarks of Sunovion Pharmaceuticals Inc. MAGNAIR is a registered trademark of PARI Pharma GmbH, used under license. SUNOVION and sunovion-icon.png.a67393b5357564161dcf26aa20cb742d.png are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. ©2020 Sunovion Pharmaceuticals Inc. All rights reserved. Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA 01752. 8/20 LON-US-00073-20

Guest
This topic is now closed to further replies.
×

By using the site you agree to our Privacy, Cookies, and Terms of Service Policies.

OK